Pfizer Inc (NYSE:PFE) shares traded -0.34% lower at $26.64 on Wall Street last session.
PFE stock price is now 1.19% away from the 50-day moving average and -3.99% away from the 200-day moving average. The market capitalization of the company currently stands at $150.98B.
On November 15, 2024, Wolfe Research recently initiated its ‘Underperform’ rating on the stock quoting a target price of $25, while ‘Citigroup’ rates the stock as ‘Neutral’
In other news, DAMICO JENNIFER B., SVP & Controller sold 2,500 shares of the company’s stock on Mar 04 ’25. The stock was sold for $64,825 at an average price of $25.93. Upon completion of the transaction, the SVP & Controller now directly owns 11,850 shares in the company, valued at $0.32 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Feb 13 ’25, Director BLAYLOCK RONALD E bought 19,457 shares of the business’s stock. A total of $499,072 was incurred on buying the stock at an average price of $25.65. This leaves the insider owning 27,707 shares of the company worth $0.74 million. A total of 0.04% of the company’s stock is owned by insiders.
During the past 12 months, Pfizer Inc has had a low of $24.48 and a high of $31.54. As of last week, the company has a debt-to-equity ratio of 0.76, a current ratio of 1.17, and a quick ratio of 0.92.
The net profit margin was 12.60% and return on equity was 9.05% for PFE. The company reported revenue of $17.76 billion for the quarter, compared to $14.57 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 21.92 percent.
